Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.
SINGAPORE: On closed-circuit television (CCTV) footage, a masked man in dark clothes scurries across an empty road. He then disappears into the corner of the frame, before being spotted scuttling down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback